Efficacy of Exenatide-LAR Alone and in Combination With Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Uncontrolled Type 2 Diabetes

Trial Profile

Efficacy of Exenatide-LAR Alone and in Combination With Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Uncontrolled Type 2 Diabetes

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Exenatide (Primary) ; Dapagliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Dexlar
  • Most Recent Events

    • 01 Mar 2017 Status changed from recruiting to withdrawn prior to enrolment due to inability to enroll as there is widespread use of both classes of drugs in patients with T2DM, including those on concomitant insulin therapy.
    • 22 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top